PE20121084A1 - Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2 - Google Patents
Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2Info
- Publication number
- PE20121084A1 PE20121084A1 PE2011002058A PE2011002058A PE20121084A1 PE 20121084 A1 PE20121084 A1 PE 20121084A1 PE 2011002058 A PE2011002058 A PE 2011002058A PE 2011002058 A PE2011002058 A PE 2011002058A PE 20121084 A1 PE20121084 A1 PE 20121084A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- amount
- dosage form
- pharmaceutical dosage
- active ingredient
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 2
- 102000051485 Bcl-2 family Human genes 0.000 title 1
- 108700038897 Bcl-2 family Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000002904 solvent Substances 0.000 abstract 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- -1 AMINO Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 abstract 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 abstract 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 abstract 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical class [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- GEAXLHPORCRESC-UHFFFAOYSA-N chlorocyclohexatriene Chemical class ClC1=CC=C=C[CH]1 GEAXLHPORCRESC-UHFFFAOYSA-N 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
- 229940035044 sorbitan monolaurate Drugs 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 150000003462 sulfoxides Chemical class 0.000 abstract 1
- 239000002562 thickening agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
REFERIDA A UNA FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE: A) UN PRINCIPIO ACTIVO DE N-(4-(4-((2-(4-CLOROFENIL)-5,5-DIMETIL-1-CICLOHEX-1-EN-1-IL)-METIL)PIPERAZIN-1-IL)BENZOIL)-4-(((1R)-3-(MORFOLIN-4-IL)-1-((FENILSULFANIL)FENIL)PROPIL)AMINO)-3-((TRIFLUOROMETIL)SULFONIL)BENCENOSULFAMIDA EN UNA CANTIDAD DE 0,5-40%; B) UN POLIMERO FARMACEUTICAMENTE ACEPTABLE SELECCIONADO DE COPOLIMERO N-VINIL PIRROLIDONA Y ACETATO DE VINILO EN UNA CANTIDAD DE 40-97,5% EN PESO; C) UN SOLUBILIZANTE SELECCIONADO DE SOLUBILIZANTE NO IONICO TAL COMO ALFA TOCOFERILO POLIETILENGLICOL SUCCINATO, MONOLAURATO DE SORBITAN Y POLIOXIETILEN MONOLAURATO DE SORBITAN, ENTRE OTROS; SOLUBILIZANTES TAL COMO LAURILSULFATO DE SODIO, Y COMBINACIONES DE LOS MISMOS EN UNA CANTIDAD DE 2-20%; D) UN SOLVENTE NO VOLATIL LIQUIDO A TEMPERATURA AMBIENTE PARA EL PRINCIPIO ACTIVO TAL COMO PROPILENGLICOL; E) AL MENOS UN ADITIVO SELECCIONADO DE REGULADORES DE FLUJO, DESINTEGRANTES, AGENTES ESPESANTES Y LUBRICANTES EN UNA CANTIDAD DE 0-15% EN PESO. COMPRENDE ADEMAS MENOS DE 1,5% EN PESO EN RELACION AL PESO DEL INGREDIENTE ACTIVO DE PRODUCTOS DE DESCOMPOSICION CON SULFOXIDO DEL INGREDIENTE ACTIVO. DICHA COMPOSICION ES UNA DISPERSION SOLIDA UTIL EN EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18513009P | 2009-06-08 | 2009-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121084A1 true PE20121084A1 (es) | 2012-09-13 |
Family
ID=43063251
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002532A PE20160043A1 (es) | 2009-06-08 | 2010-06-08 | Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2 |
| PE2011002058A PE20121084A1 (es) | 2009-06-08 | 2010-06-08 | Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002532A PE20160043A1 (es) | 2009-06-08 | 2010-06-08 | Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2 |
Country Status (37)
| Country | Link |
|---|---|
| US (6) | US9642796B2 (es) |
| EP (3) | EP2440177B1 (es) |
| JP (2) | JP5872459B2 (es) |
| KR (2) | KR101751216B1 (es) |
| CN (2) | CN102802606A (es) |
| AR (2) | AR077021A1 (es) |
| AU (1) | AU2010258367B2 (es) |
| BR (2) | BRPI1012831B1 (es) |
| CA (1) | CA2763441C (es) |
| CL (1) | CL2011003054A1 (es) |
| CO (1) | CO6480964A2 (es) |
| CR (1) | CR20170037A (es) |
| CY (1) | CY1119663T1 (es) |
| DK (2) | DK2440177T3 (es) |
| DO (2) | DOP2011000375A (es) |
| EC (1) | ECSP12011580A (es) |
| ES (2) | ES2551860T3 (es) |
| HR (2) | HRP20151342T1 (es) |
| HU (2) | HUE025638T2 (es) |
| IL (2) | IL216494A (es) |
| LT (1) | LT2982366T (es) |
| MX (1) | MX2011013164A (es) |
| MY (1) | MY159824A (es) |
| NO (1) | NO2982366T3 (es) |
| NZ (1) | NZ597241A (es) |
| PE (2) | PE20160043A1 (es) |
| PL (2) | PL2982366T3 (es) |
| PT (2) | PT2440177E (es) |
| RU (2) | RU2568599C2 (es) |
| SG (1) | SG176264A1 (es) |
| SI (2) | SI2440177T1 (es) |
| SM (1) | SMT201500317B (es) |
| TW (2) | TWI471321B (es) |
| UA (1) | UA104471C2 (es) |
| UY (1) | UY32695A (es) |
| WO (1) | WO2010143074A2 (es) |
| ZA (1) | ZA201108853B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI471321B (zh) | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| SG2014013502A (en) | 2010-06-09 | 2014-05-29 | Abbvie Inc | Solid dispersions containing kinase inhibitors |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| RU2598345C2 (ru) * | 2010-10-29 | 2016-09-20 | Эббви Инк. | Твердые дисперсии, содержащие средства, вызывающие апоптоз |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| TWI535701B (zh) | 2010-11-23 | 2016-06-01 | 艾伯維巴哈馬有限公司 | 使用選擇性ｂｃｌ－２抑制劑之治療方法 |
| NZ610151A (en) | 2010-11-23 | 2015-06-26 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
| KR102191562B1 (ko) * | 2012-11-07 | 2020-12-15 | 에스케이바이오팜 주식회사 | 난용성 약물의 고체분산체 및 이의 제조방법 |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2014160071A1 (en) * | 2013-03-14 | 2014-10-02 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of glutamine-addicted cancers |
| WO2015051252A1 (en) * | 2013-10-03 | 2015-04-09 | Duke University | Compositions and methods for treating cancer with jak2 activity |
| US20170021033A1 (en) * | 2014-03-12 | 2017-01-26 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| BR112016024421A2 (pt) * | 2014-06-18 | 2017-08-15 | Chugai Pharmaceutical Co Ltd | composição farmacêutica, cápsula e uso da composição farmacêutica |
| CN105616419A (zh) * | 2014-11-07 | 2016-06-01 | 江苏豪森药业集团有限公司 | 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法 |
| CN113925833A (zh) | 2016-02-29 | 2022-01-14 | 豪夫迈·罗氏有限公司 | 包含酪氨酸蛋白激酶抑制剂的剂型组合物 |
| JOP20190191A1 (ar) | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
| US11872237B2 (en) | 2018-12-28 | 2024-01-16 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and preparation method thereof |
| US11285159B2 (en) | 2019-11-05 | 2022-03-29 | Abbvie Inc. | Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax |
| JP2023514750A (ja) * | 2020-02-24 | 2023-04-07 | グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド | Ｂｃｌ２阻害剤を含むホットメルト押出し固体分散体 |
| CN114533677A (zh) * | 2020-11-25 | 2022-05-27 | 苏州亚盛药业有限公司 | 固体分散体、制剂、其制备方法及其应用 |
| MX2023008155A (es) * | 2021-01-08 | 2023-07-24 | Syros Pharmaceuticals Inc | Regimenes de tratamiento con dosis fijas de tamibaroteno. |
| CN113520995B (zh) * | 2021-08-16 | 2023-03-10 | 海南鑫开源医药科技有限公司 | 一种离子敏感型眼用原位凝胶、其制备方法及应用 |
| WO2023172958A1 (en) * | 2022-03-08 | 2023-09-14 | Onkosxcel Therapeutics, Llc | Stable formulations of talabostat |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
| GB9309509D0 (en) * | 1993-05-07 | 1993-06-23 | Merck Patent Gmbh | Thrombin inhibitors |
| IL111004A (en) * | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
| US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| DE69434626D1 (de) * | 1993-11-17 | 2006-04-20 | Athena Neurosciences Inc | Transparente flüssigkeit zur verabreichung von verkapselten medikamenten |
| US5759548A (en) * | 1993-11-30 | 1998-06-02 | Lxr Biotechnology Inc. | Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
| BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| US5891469A (en) | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
| BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| US6982281B1 (en) * | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| US20020055631A1 (en) * | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| DE60113731T2 (de) * | 2001-01-31 | 2006-06-29 | Pfizer Products Inc., Groton | Als inhibitoren von pde4-isozymen geeignete etherderivate |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| PT1471887E (pt) * | 2002-02-04 | 2010-07-16 | Elan Pharma Int Ltd | Composiães de nanopartculas com lisozima como um estabilizador superficial |
| US20050163835A1 (en) * | 2002-02-26 | 2005-07-28 | Astrazeneca Ab | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| TWI262077B (en) * | 2002-04-29 | 2006-09-21 | Merck & Co Inc | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
| US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
| US7318503B2 (en) | 2004-04-26 | 2008-01-15 | Akebono Corporation (North America) | Pad retaining clips |
| FR2875409B1 (fr) * | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
| DK1888550T3 (da) * | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| CN1706371B (zh) | 2005-05-27 | 2010-11-10 | 沈阳药科大学 | 一种高效的马蔺子素制剂及其制备方法 |
| SI1933809T1 (sl) | 2005-10-11 | 2012-08-31 | Yissum Res Dev Co | Sestavki za mazalno dajanje |
| US20070104780A1 (en) * | 2005-10-25 | 2007-05-10 | Lipari John M | Formulation comprising a drug of low water solubility and method of use thereof |
| US7151188B1 (en) | 2005-11-16 | 2006-12-19 | General Electric Company | Process for the production of mercaptoalkylalkoxysilanes |
| EP2037912A2 (en) * | 2006-05-15 | 2009-03-25 | Encysive Pharmaceuticals, Inc. | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist |
| US20080004286A1 (en) * | 2006-06-30 | 2008-01-03 | Schering Corporation | Method of Using Substituted Piperidines that Increase P53 Activity |
| EP1880715A1 (en) * | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| WO2008030836A2 (en) * | 2006-09-05 | 2008-03-13 | Abbott Laboratories | Bcl inhibitors treating platelet excess |
| WO2008064116A2 (en) * | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| RU2351352C2 (ru) | 2007-04-09 | 2009-04-10 | Закрытое акционерное общество "Санкт-Петербургский институт фармации" | Твердая нанокомпозиция для доставки биологически активных веществ |
| US8536157B2 (en) | 2007-04-13 | 2013-09-17 | The University Of Melbourne | Non-steroidal compounds |
| CN101861165A (zh) * | 2007-10-12 | 2010-10-13 | 麻省理工学院 | 疫苗纳米技术 |
| EP2219651A1 (en) * | 2007-12-06 | 2010-08-25 | Abbott Laboratories | Oral compositions of abt-263 for treating cancer |
| CN101220008B (zh) | 2008-01-21 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 化合物abt-263的合成方法 |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| US20100280031A1 (en) | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
| US20100278921A1 (en) * | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US20100297194A1 (en) * | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI532484B (zh) | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| TWI471321B (zh) | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| CA2764187A1 (en) * | 2009-06-18 | 2010-12-23 | Abbott Laboratories | Stable nanoparticulate drug suspension |
| KR20120085781A (ko) | 2009-09-20 | 2012-08-01 | 아보트 러보러터리즈 | Ｂｃｌ-２ 단백질 관련 질환을 치료하는데 사용하기 위한 ａｂｔ-２６３ 결정 형태 및 용매화물 |
| SG181916A1 (en) | 2009-12-22 | 2012-08-30 | Abbott Lab | Abt-263 capsule |
| CN101798292A (zh) | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | ABT-263衍生的新型Bcl-2蛋白抑制剂的制备 |
| JP6095678B2 (ja) | 2011-11-11 | 2017-03-15 | エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド | 薬剤パッケージ用の不動態化、ｐＨ保護又は滑性皮膜、被覆プロセス及び装置 |
-
2010
- 2010-06-07 TW TW99118493A patent/TWI471321B/zh not_active IP Right Cessation
- 2010-06-07 TW TW103146100A patent/TWI540132B/zh active
- 2010-06-08 PT PT107428757T patent/PT2440177E/pt unknown
- 2010-06-08 BR BRPI1012831-0A patent/BRPI1012831B1/pt active IP Right Grant
- 2010-06-08 CN CN2010800349262A patent/CN102802606A/zh active Pending
- 2010-06-08 DK DK10742875.7T patent/DK2440177T3/en active
- 2010-06-08 NO NO15184904A patent/NO2982366T3/no unknown
- 2010-06-08 LT LTEP15184904.9T patent/LT2982366T/lt unknown
- 2010-06-08 HU HUE10742875A patent/HUE025638T2/en unknown
- 2010-06-08 BR BR122018076978-5A patent/BR122018076978B1/pt active IP Right Grant
- 2010-06-08 SG SG2011087715A patent/SG176264A1/en unknown
- 2010-06-08 US US12/796,000 patent/US9642796B2/en active Active
- 2010-06-08 PT PT151849049T patent/PT2982366T/pt unknown
- 2010-06-08 WO PCT/IB2010/001659 patent/WO2010143074A2/en not_active Ceased
- 2010-06-08 ES ES10742875.7T patent/ES2551860T3/es active Active
- 2010-06-08 PE PE2015002532A patent/PE20160043A1/es unknown
- 2010-06-08 JP JP2012514556A patent/JP5872459B2/ja not_active Expired - Fee Related
- 2010-06-08 SI SI201031076T patent/SI2440177T1/sl unknown
- 2010-06-08 EP EP10742875.7A patent/EP2440177B1/en active Active
- 2010-06-08 CR CR20170037A patent/CR20170037A/es unknown
- 2010-06-08 RU RU2011154143/15A patent/RU2568599C2/ru active
- 2010-06-08 KR KR1020127000350A patent/KR101751216B1/ko active Active
- 2010-06-08 HR HRP20151342TT patent/HRP20151342T1/hr unknown
- 2010-06-08 ES ES15184904.9T patent/ES2651307T3/es active Active
- 2010-06-08 EP EP17181461.9A patent/EP3272334B1/en not_active Not-in-force
- 2010-06-08 CN CN201610756594.8A patent/CN106074391A/zh active Pending
- 2010-06-08 MY MYPI2011005920A patent/MY159824A/en unknown
- 2010-06-08 HU HUE15184904A patent/HUE035727T2/en unknown
- 2010-06-08 PL PL15184904T patent/PL2982366T3/pl unknown
- 2010-06-08 NZ NZ597241A patent/NZ597241A/en unknown
- 2010-06-08 AU AU2010258367A patent/AU2010258367B2/en active Active
- 2010-06-08 MX MX2011013164A patent/MX2011013164A/es active IP Right Grant
- 2010-06-08 KR KR1020177016486A patent/KR101791404B1/ko not_active Expired - Fee Related
- 2010-06-08 RU RU2015141869A patent/RU2711359C2/ru active
- 2010-06-08 UA UAA201200189A patent/UA104471C2/uk unknown
- 2010-06-08 SI SI201031605T patent/SI2982366T1/en unknown
- 2010-06-08 UY UY0001032695A patent/UY32695A/es active IP Right Grant
- 2010-06-08 PE PE2011002058A patent/PE20121084A1/es active IP Right Grant
- 2010-06-08 CA CA2763441A patent/CA2763441C/en not_active Expired - Fee Related
- 2010-06-08 AR ARP100102011A patent/AR077021A1/es not_active Application Discontinuation
- 2010-06-08 PL PL10742875T patent/PL2440177T3/pl unknown
- 2010-06-08 DK DK15184904.9T patent/DK2982366T3/en active
- 2010-06-08 EP EP15184904.9A patent/EP2982366B1/en active Active
-
2011
- 2011-11-20 IL IL216494A patent/IL216494A/en active IP Right Grant
- 2011-12-01 ZA ZA2011/08853A patent/ZA201108853B/en unknown
- 2011-12-02 CL CL2011003054A patent/CL2011003054A1/es unknown
- 2011-12-05 DO DO2011000375A patent/DOP2011000375A/es unknown
- 2011-12-28 CO CO11180119A patent/CO6480964A2/es active IP Right Grant
-
2012
- 2012-01-06 EC EC2012011580A patent/ECSP12011580A/es unknown
-
2015
- 2015-04-26 IL IL238477A patent/IL238477A/en active IP Right Grant
- 2015-12-17 SM SM201500317T patent/SMT201500317B/it unknown
-
2016
- 2016-01-12 JP JP2016003239A patent/JP6129999B2/ja active Active
-
2017
- 2017-03-07 DO DO2017000057A patent/DOP2017000057A/es unknown
- 2017-03-22 US US15/466,673 patent/US20170189426A1/en not_active Abandoned
- 2017-10-05 AR ARP170102786A patent/AR109816A2/es unknown
- 2017-12-06 CY CY20171101285T patent/CY1119663T1/el unknown
- 2017-12-07 HR HRP20171902TT patent/HRP20171902T1/hr unknown
-
2019
- 2019-05-17 US US16/415,651 patent/US20190269704A1/en not_active Abandoned
-
2020
- 2020-12-04 US US17/112,742 patent/US20210093649A1/en not_active Abandoned
-
2021
- 2021-12-20 US US17/645,244 patent/US20220110951A1/en not_active Abandoned
-
2023
- 2023-08-29 US US18/457,738 patent/US20240197757A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121084A1 (es) | Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2 | |
| CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
| CL2011002781A1 (es) | Compuestos (e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol y (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol; composicion farmaceutica que los comprende; y uso en el tratamiento del cancer. | |
| DK2207770T3 (da) | 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| PE20191108A1 (es) | Inhibidores selectivos de jak1 | |
| CL2008002746A1 (es) | Compuestos derivados de 4-(4-aril-o-fenil)-1h-piridin-2-ona; 4-(4-aril-s-fenil)-1h-piridin-2-ona; 4-(4-aril-so-fenil)-1h-piridin-2-ona; 4-(4-aril-so2-fenil)-1h-piridin-2-ona y 4-(4-aril-cf2-fenil)-1h-piridin-2-ona 1,3-disustituida; composicion que los comprende; y uso para el tratamiento y/o prevencion de trastornos del snc que involucran al receptor mglur2. | |
| PH12014502331A1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| UY29182A1 (es) | "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones" | |
| CL2008002768A1 (es) | Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades. | |
| CO6761298A2 (es) | Combinaciones que comprenden antipsicóticos atípocos y antagonistas taar1 | |
| CY1116190T1 (el) | Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτην | |
| CL2009000256A1 (es) | Imidazolinas fenil sustituidas, composicion farmaceutica que contenga estos compuestos y su uso en el sindrome metabolico, obesidad, diabetes, sindrome de stein-leventhal, transtornos del snc, esquizofrenia, alzheimer, dependencia al alcohol y dependencia a la nicotina. | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| AR039936A1 (es) | Formulacion farmaceutica de liberacion modificada | |
| JOP20190053A1 (ar) | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط | |
| CL2008002316A1 (es) | Compuestos heterociclicos nitrogenados que contienen fenilendiamina sustituida, inhibidores de la interaccion entre mdm2 y p53; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento del cancer. | |
| PE20191792A1 (es) | Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos | |
| PE20140792A1 (es) | Composiciones farmaceuticas | |
| CL2009001146A1 (es) | Compuestos derivados de 5-(5-(2-(3,5-bis(trifluorometil)fenil)-n,2-dimetilpropanoamida)-4-(4-fluoro-2-metilfenil)piridin-2-il)pirrolidin-2-carboxamida, antagonistas de los receptores nk-1; composicion farmaceutica; y uso del compuesto para el tratamiento de la depresion; ansiedad, trastornos del sueño o emesis. | |
| EA201991490A1 (ru) | Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1 | |
| EA201300857A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| PE20141789A1 (es) | Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |